indazoles has been researched along with Carcinoma, Transitional Cell in 14 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (14.29) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 12 (85.71) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bellmunt, J; Bossé, D; Choueiri, TK; Harshman, LC; Jacobus, S; Lalani, AA; Lundgren, K; Moreno, I; Polacek, L; Rosenberg, JE; Takeda, DY; Van Allen, EM; Wagle, N; Wankowicz, SA | 1 |
| Arndt, C; Ecke, TH; Eimer, C; Georgas, E; Gerullis, H; Otto, T | 1 |
| Amantini, C; Berardi, R; Bonfili, L; Burattini, L; Cascinu, S; Eleuteri, AM; Farfariello, V; Liberati, S; Morelli, MB; Mozzicafreddo, M; Nabissi, M; Santoni, G; Santoni, M | 1 |
| Erlichman, C; Flynn, PJ; Ho, WM; Miles, KM; Millward, M; Picus, J; Pili, R; Pitot, H; Qin, R; Tan, W; Vaishampayan, U | 1 |
| Crippa, F; Daidone, MG; De Braud, FG; Farè, E; Giannatempo, P; Gianni, AM; Landoni, E; Lanocita, R; Mariani, L; Messina, C; Morosi, C; Necchi, A; Nicolai, N; Ortega, C; Pennati, M; Raggi, D; Sacco, C; Salvioni, R; Sava, T; Schwartz, LH; Zaffaroni, N | 1 |
| Choueiri, TK; Cleary, JM; Elfiky, AA; Gabriel, SB; Gandhi, L; Garraway, LA; Grabiner, BC; Hodis, E; Jacobus, S; Kantoff, PW; Lander, ES; Loda, M; Rosenberg, JE; Sabatini, DM; Shapiro, GI; Signoretti, S; Stack, EC; Stewart, M; Supko, JG; Taplin, ME; Van Allen, EM; Wagle, N | 1 |
| Ali, SM; Morris, JC; Pal, SK; Palma, N; Ross, JS | 1 |
| Berger, MF; Canevari, S; Colecchia, M; De Braud, FG; Giannatempo, P; Iyer, G; Necchi, A; Pierotti, MA; Pinciroli, P; Raggi, D; Rosenberg, JE; Solit, DB; Won, H | 1 |
| Bokemeyer, C; Oechsle, K; Oing, C; Rink, M; Seidel, C; von Amsberg, G | 1 |
| Giri, S; Hahn, AW; Martin, MG; Patel, D; Sluder, H; Vanderwalde, A | 1 |
| Fan, A; Haas, D; Harshman, L; Lam, A; Li, S; Narayanan, S; Pachynski, R; Poushnejad, S; Srinivas, S; Vaishampayan, U | 1 |
| Li, S; Li, Y; Tang, H; Wang, Y; Xu, R; Zhang, L; Zhao, X; Zhong, Z | 1 |
| Coptcoat, M; Masters, JR; Popert, RJ; Zupi, G | 1 |
| Belmonte, P; Francini, M; Lo Re, G; Monfardini, S; Morassut, S; Tumolo, S; Veronesi, A | 1 |
1 review(s) available for indazoles and Carcinoma, Transitional Cell
| Article | Year |
|---|---|
Second Line Chemotherapy for Advanced and Metastatic Urothelial Carcinoma: Vinflunine and Beyond-A Comprehensive Review of the Current Literature.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biological Factors; Carboplatin; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Indazoles; Neoplasm Recurrence, Local; Paclitaxel; Pemetrexed; Pyrimidines; Salvage Therapy; Sulfonamides; Urinary Bladder Neoplasms; Vinblastine | 2016 |
6 trial(s) available for indazoles and Carcinoma, Transitional Cell
| Article | Year |
|---|---|
Everolimus and pazopanib (E/P) benefit genomically selected patients with metastatic urothelial carcinoma.
Topics: Carcinoma, Transitional Cell; DNA Copy Number Variations; Everolimus; Female; High-Throughput Nucleotide Sequencing; Humans; Indazoles; Kidney Neoplasms; Male; Microtubule-Associated Proteins; Mutation; Pyrimidines; Receptor, Fibroblast Growth Factor, Type 3; Sequence Analysis, DNA; Sulfonamides; Survival Analysis; Treatment Outcome; Tuberous Sclerosis Complex 1 Protein; Tuberous Sclerosis Complex 2 Protein | 2018 |
Combined treatment with pazopanib and vinflunine in patients with advanced urothelial carcinoma refractory after first-line therapy.
Topics: Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cardiovascular Diseases; Chemical and Drug Induced Liver Injury; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Early Termination of Clinical Trials; Humans; Indazoles; Male; Neutropenia; Organoplatinum Compounds; Palliative Care; Prospective Studies; Pyrimidines; Salvage Therapy; Sulfonamides; Thrombocytopenia; Urologic Neoplasms; Vinblastine | 2013 |
A phase II safety and efficacy study of the vascular endothelial growth factor receptor tyrosine kinase inhibitor pazopanib in patients with metastatic urothelial cancer.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Carcinoma, Transitional Cell; Disease-Free Survival; Female; Humans; Indazoles; Male; Middle Aged; Neovascularization, Pathologic; Pyrimidines; Receptors, Vascular Endothelial Growth Factor; Sulfonamides; Treatment Failure; Urologic Neoplasms; Urothelium | 2013 |
Analysis of plasma cytokines and angiogenic factors in patients with pretreated urothelial cancer receiving Pazopanib: the role of circulating interleukin-8 to enhance the prognostic accuracy.
Topics: Angiogenesis Inducing Agents; Angiogenesis Inhibitors; Biomarkers, Tumor; Carcinoma, Transitional Cell; Cytokines; Enzyme-Linked Immunosorbent Assay; Humans; Indazoles; Interleukin-8; Multimodal Imaging; Positron-Emission Tomography; Prognosis; Proportional Hazards Models; Pyrimidines; Sulfonamides; Tomography, X-Ray Computed; Urologic Neoplasms | 2014 |
Activating mTOR mutations in a patient with an extraordinary response on a phase I trial of everolimus and pazopanib.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Drug Administration Schedule; Everolimus; Female; High-Throughput Nucleotide Sequencing; Humans; Indazoles; Lymphatic Metastasis; Male; Middle Aged; Mutation; Precision Medicine; Pyrimidines; Radionuclide Imaging; Sequence Analysis, DNA; Sulfonamides; TOR Serine-Threonine Kinases; Urinary Bladder Neoplasms | 2014 |
Phase II Study of Pazopanib and Paclitaxel in Patients With Refractory Urothelial Cancer.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Drug Administration Schedule; Female; Humans; Indazoles; Male; Middle Aged; Neoplasm Metastasis; Paclitaxel; Pyrimidines; Sulfonamides; Survival Analysis; Treatment Outcome; Urologic Neoplasms | 2016 |
7 other study(ies) available for indazoles and Carcinoma, Transitional Cell
| Article | Year |
|---|---|
Pazopanib and sunitinib trigger autophagic and non-autophagic death of bladder tumour cells.
Topics: Antineoplastic Agents; Autophagy; Carcinoma, Squamous Cell; Carcinoma, Transitional Cell; Cell Death; Cell Line, Tumor; Cell Survival; Humans; Indazoles; Indoles; Inhibitory Concentration 50; Membrane Potential, Mitochondrial; Necrosis; Protein-Tyrosine Kinases; Pyrimidines; Pyrroles; Reactive Oxygen Species; Sulfonamides; Sunitinib; Urinary Bladder Neoplasms | 2013 |
Exceptional Response to Pazopanib in a Patient with Urothelial Carcinoma Harboring FGFR3 Activating Mutation and Amplification.
Topics: Aged; Angiogenesis Inhibitors; Carcinoma, Transitional Cell; Female; Gene Amplification; Humans; Indazoles; Lung Neoplasms; Mutation; Pyrimidines; Receptor, Fibroblast Growth Factor, Type 3; Sulfonamides; Urinary Bladder Neoplasms | 2015 |
Molecular Signature of Response to Pazopanib Salvage Therapy for Urothelial Carcinoma.
Topics: Angiogenesis Inhibitors; Carcinoma, Transitional Cell; DNA Copy Number Variations; DNA Mutational Analysis; Drug Resistance, Neoplasm; Humans; Indazoles; Mutation, Missense; Pyrimidines; Salvage Therapy; Sulfonamides; Treatment Outcome; Urinary Bladder Neoplasms | 2016 |
Next-Generation Sequencing and In Silico Analysis Facilitate Prolonged Response to Pazopanib in a Patient With Metastatic Urothelial Carcinoma of the Renal Pelvis.
Topics: Carcinoma, Transitional Cell; Computer Simulation; Female; High-Throughput Nucleotide Sequencing; Humans; Indazoles; Kidney Pelvis; Middle Aged; Models, Molecular; Mutation; Neoplasm Metastasis; Proto-Oncogene Proteins c-kit; Pyrimidines; Receptor, ErbB-2; Receptor, Platelet-Derived Growth Factor beta; Sulfonamides; Urothelium | 2015 |
Effects of YC-1 on hypoxia-inducible factor 1 alpha in hypoxic human bladder transitional carcinoma cell line T24 cells.
Topics: Antineoplastic Agents; Apoptosis; Blotting, Western; Carcinoma, Transitional Cell; Cell Hypoxia; Cell Line, Tumor; Cell Movement; Cell Proliferation; Dose-Response Relationship, Drug; Extracellular Signal-Regulated MAP Kinases; Flow Cytometry; Gene Expression Regulation, Neoplastic; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Indazoles; Matrix Metalloproteinase 2; p38 Mitogen-Activated Protein Kinases; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-bcl-2; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Signal Transduction; Up-Regulation; Urinary Bladder Neoplasms; Vascular Endothelial Growth Factor A | 2012 |
Relative cytotoxicities of adriamycin and epirubicin in combination with lonidamine against human bladder cancer cell lines.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Doxorubicin; Drug Resistance, Multiple; Epirubicin; Humans; Indazoles; Tumor Cells, Cultured; Urinary Bladder Neoplasms | 1995 |
Partial response to lonidamine of advanced bladder carcinoma: a case report.
Topics: Aged; Antineoplastic Agents; Carcinoma, Transitional Cell; Female; Humans; Indazoles; Pyrazoles; Urinary Bladder Neoplasms | 1990 |